ATF4 and osteosarcoma: Instead of transactivating HSPA5 in OS cells 7, 8, ATF4 negatively regulates GRP78 transcription in BTZ-resistant OS cells, thus reinforcing the therapeutic effect of BTZ by the dual targeting of GRP78 and RET in the context of osteosarcoma chemoresistance (Figure 8E).